Why the study?
Is edoxaban cost-effective compared to warfarin for the treatment of adults with VTE?
Is edoxaban cost-effective compared to warfarin for the treatment of adults with VTE?
Edoxaban is a cost-effective alternative to warfarin for the treatment of VTE in the US healthcare system, with an ICER of $22,057 per QALY gained.
No takes yet. Share an insight, caveat, or question.
Edoxaban may be cost-effective for VTE from the U.S. payer perspective; leaves open need for real-world validation before practice change.
Preblick et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: